CNBC · General

Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator

· By Elsa Ohlen
Story summary

Novo Nordisk rose as much as 4% after England's drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes.

Read at CNBC

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.